Chris wiwi, ph.d.
Chris Wiwi is Director and head of Analytical Research & Development, part of the Cell Therapy Development and Operations (CTDO) team at Celgene, located in Warren, New Jersey. Chris leads analytical development and QC efforts for the advancement of Celgene’s novel cellular therapy candidates from research to clinical and commercial manufacturing. He also serves as the CMC lead for bb2121, an autologous anti-BCMA CAR T cell therapy that Celgene is developing in collaboration with bluebird bio for the treatment of multiple myeloma. Chris’ team is responsible for the selection, development and validation of analytical methods to assess cellular product identity, purity, safety, quality and potency. The QC Ops team, under Chris’ leadership, provides quality testing support for the cellular products manufactured at Celgene. Prior to joining Celgene, he worked in biologics at Schering-Plough and Merck as a leader in large molecule analytics. His teams led the development and validation of biomarker, pharmacokinetics and immunogenicity assays for multiple biologics programs. Chris received his B.S. in Biology from the University of Notre Dame, Ph.D. in Cell and Molecular Biology from Boston University and carried out postdoctoral research at Johnson & Johnson.